Etripamil significantly improved PSVT -related symptoms. Satisfaction and effectiveness of at-home, nasal spray therapy for PSVT were higher for etripamil than placebo. Etripamil tended to reduce need for emergency room medical interventions for PSVT. These data support continued development of etripamil
In a new study, etripamil, a rapid- and short-acting investigational medication formulated to be delivered via nasal spray, restored a normal
Milestone Pharmaceuticals has announced the initiation of the RAPID Phase 3 trial of etripamil nasal spray for the treatment of paroxysmal
Etripamil nasal spray shows promise for treating PSVT at home.
the efficacy and safety of self-administration of etripamil versus placebo nasal spray in patients with PSVT 156 subjects experienced a vagal maneuver-refractory, symptomatic episode of confirmed PSVT; 107 subjects self-administered etripamil and 49 administered placebo nasal spray with 2:1 randomization (Figure 1).
Etripamil is Milestone's lead investigational product. It is a novel calcium channel blocker nasal spray being developed for elevated and often
If approved, we believe that etripamil nasal spray will be a valuable treatment option for patients suffering from PSVT. The NDA for etripamil
Etripamil nasal spray was effective and well tolerated to induce PSVT termination for up to 60 min. Therefore, etripamil nasal spray constitutes a promising strategy for PSVT self-termination without medical supervision; however, further RCTs are required before endorsement in clinical practice.
etripamil nasal spray for the treatment of paroxysmal supraventricular tachycardia (PSVT). Per the FDA, the NDA for etripamil to treat PSVT
Comments